Chlormezanone in primary fibromyalgia syndrome: A double blind placebo controlled study

Rheumatology

Volumn 32, Issue 1, 1993, Pages 55-58

  Pattrick, M ^a   Swannell, A ^a   Doherty, M ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Chlormezanone; Fibromyalgia; Sleep disturbance

Indexed keywords

ANXIOLYTIC AGENT; CHLORMEZANONE; PLACEBO;

ADULT; AGED; ALERTNESS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FIBROMYALGIA; HEADACHE; HUMAN; MOOD; MORNING STIFFNESS; MUSCLE RELAXATION; NAUSEA; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PATIENT SATISFACTION; PRIORITY JOURNAL; SLEEP; SLEEP DISORDER;

ADULT; AFFECT; AGED; CHLORMEZANONE; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FIBROMYALGIA; HUMAN; MIDDLE AGE; PAIN; SLEEP; SUPPORT, NON-U.S. GOV'T; SYNDROME;

EID: 0027393614     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/32.1.55     Document Type: Article

References (32)

1. Yunnus MB, Masi AT, Callabfo JJ, Miller KA, Feigenbaum SL. Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched controls. Semin Arthritis Rheum 1981;11:151-72.
2. Moldofsky H, Scarisbrick P. Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1975; 38:35-44.
3. Moldofsky H, Scarisbrick P, England R, Smythe H. Musculoskeletal symptoms and non REM sleep disturbance in patients with ‘fibrositis syndrome’ and healthy subjects. Psychosom Med 1975;37:341-51.
4. Cathey MA, Wolfe F, Kleinheksel SM. Socioeconomic impact of fibrositis. Am J Med 1986; 81:78-84.
5. Clark S, Tindall E, Bennett RM. A double blind crossover trial of prednisolone versus placebo in the treatment of fibrositis. J Rheumatol 1985;12:980-3.
6. McCain GA, Bell DA, Mai FM, Halliday PE. A controlled study of the effects of a supervised cardiovascular fitness training program on the manifestations of primary fibromyalgia. Arthritis Rheum 1988;31:1135-41.
7. Bennett RM, Clark CR, Goldberg L, et al. Aerobic fitness in patients with fibrositis. A controlled study of respiratory gas exchange and 133xenon clearance from exercising muscle. Arthritis Rheum 1989; 32: 454-60.
8. Goldenberg DL. A review of the role of tricyclic medications in the treatment of fibromyalgia syndrome. J Rheumatol 1989;16(Suppl 19):137-9.
9. Goldenberg DL, Felson DT, Dinerman H. A randomized controlled trial of amitryptiline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29;1371-7.
10. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double blind, placebo-controlled study. Arthritis Rheum 1986;29:655-9.
11. Bennett RM, Gatter RA, Campbell SM, Andrews RP, Clark SR, Scarola JA. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind placebo controlled study. Arthritis Rheum 1988;31:1535-42.
12. Barnes CD, Fung SJ, Gintautas J. Brainstem noradrenergic system depression by cyclobenzarpine. Neuropharmacology 1980;19:221-4.
13. Commissiong JW, Kroum F, Reiffenstein RJ, Neff NH. Cyclobenzaprine: a possible mechanism of action for its muscle relaxant effect. Can J Physiol Pharmacol 1981;59:37-44.
14. Kalyan-Raman UP, Kalyman-Ryan K, Yunnus MB et al. Muscle pathology in primary fibromyalgia syndrome: a light microscopic, histologic and ultrastructure study. J Rheumatol 1984;11:808-14.
15. Bengtsson A, Henrikson KG, Larson J. Muscle biopsy in primary fibromyalgia: light-microscopical and histochemical findings. Scand J Rheumatol 1986;15: 1-6.
16. Bengtsson A, Henrikson KG, Larson J. Reduced high energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 1986;29:817-21.
17. Lund N, Bengtsson A, Thorberg P. Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 1986;15:165-73.
18. Rigal J. Neurophysiological study in man of the myolytic action of chlormezanone. Inform Ther 1968; 6: 35-40.
19. Ganz SE. Clinical evaluation of a new muscle relaxant (chlormezanone). J Indiana State Med Assoc 1959; 52:1134-6.
20. McCain GA. Nonmedicinal treatments in primary fibromyalgia. Rheum Dis Clin North Am 1989;15: 73-90.
21. Felsom D, Goldenberg DL. The natural history of fibromyalgia. Arthritis Rheum 1986;29:1522-6.
22. Van Woert MH, Sethy VH. Therapy of intention myoclonus with L-5-hydroxytryptophan and a peripheral decarboxylase inhibitor, MK 486. Neurology 1975;25:135-40.
23. Sicuteri F. Headache as a possible expression of a deficiency of brain 5-hydroxytryptamine (central denervation sensitivity). Psychosom Med 1972; 12:69-72.
24. Scudds RA, McCain GA, Harth M, Rollman GB. A double-blind crossover trial of the clinical and perceptual effects of amitriptyline on fibrositis. Arthrit is Rheum 1987;30:S14.
25. Caruso I, Sarzi Puttinin PC, Boccassinin L. Doubleblind study of dothiepin versus placebo in treatment of the primary fibromyalgia syndrome. Int Med Res 1987;15:154-9.
26. Bennett RM. Muscle physiology and cold reactivity in the fibromyalgia syndrome. Rheum Dis Clin North Am 1989;15:135-47.
27. Kraft GH, Johnson EW, LaBan MM. The fibrositis syndrome. Arch Phys Med Rehab 1968;49:155-62.
28. Hobkirk D, Rhodes M, Haslock I. Night medication in rheumatoid arthritis: II. Combined therapy with indomethacin and diazepam. Rheumatol Rehabil 1977;16:125-7.
29. Cohen L. A controlled study of Trancopal in sleep disturbances due to rheumatic disease. J Int Med Res 1978;6:111-14.
30. Condie R. Chlormezanone in the treatment of insomnia due to rheumatic stiffness. Curr Med Res Opin 1979;6:217-20.
31. Wojtulewski JA, Walter J. Treatment of sleep disturbance in arthritis with chlormezanone. Curr Med Res Opin 1983;8:456-60.
32. Oswald I. Sleep studies in clinical pharmacology. BrJ Clin Pharmacol 1980;10:317-26.